If Pfizer's vaccine is a winner, why did this analyst downgrade its stock?

Mizuho Securities' Vamil Divan expresses concern about the company's post-coronavirus future.

| More on:

Should you invest $1,000 in Alphabet right now?

Before you buy Alphabet shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Alphabet wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

woman carrying out an experiment with a pipette and petri dish

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Pfizer (NYSE: PFE) had a fine first quarter by many standards. Fueled by widespread demand for its BNT162b2 coronavirus vaccine, it crushed both trailing and forward analyst estimates.

One prognosticator following the company, however, isn't ready to pop the Champagne. On Thursday -- two days after those quarterly results were published -- Vamil Divan of Mizuho Securities downgraded his recommendation on the stock from buy to neutral. He maintained his $42 per share price target, which is about 7% above where it's currently trading.

The analyst credited Pfizer with a "stunning beat" in his new research note. However, he wrote, "Cash flows from COVID-19 vaccine sales provide Pfizer with greater optionality, but we wait to see how Pfizer allocates that capital before assessing whether they have improved their 2026-2030 outlook."

As with any pharmaceutical company, Pfizer's future depends greatly on its pipeline. Since much of the focus on Pfizer as a company and as a stock has, understandably, been on BNT162b2 over the past year, more attention needs to be paid to its research and development activities.

"While Pfizer's near-term outlook remains strong and has been boosted by their COVID-19 vaccine, we believe it will be important for these pipeline catalysts to deliver in the coming months in order for investors to gain more comfort with Pfizer's outlook beyond the next four years and drive Pfizer shares meaningfully higher," Divan wrote.

BNT162b2 is currently in widespread use in countries around the world, and particularly in the U.S., where it is one of only three coronavirus vaccines authorized for emergency use by the FDA. However, both cases and fatalities have been dropping significantly in the country.

Pfizer's shares closed Thursday's trading session down by 1%, against the 0.8% rise of the S&P 500 index.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

A man looking at his laptop and thinking.
International Stock News

Amazon: A good quarter but some concerns

Here's our initial take on Amazon's financial report.

Read more »

Man looks up at apple on his head.
International Stock News

Apple: Growth in a difficult environment

Here's our initial take on Apple's financial report.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Why Microsoft stock popped this week

Microsoft stock was up by 9.5% this week.

Read more »

Electric vehicle such as Tesla being charged at charging station.
International Stock News

Tesla searches for Musk successor: Why this matters

Could Elon get the chainsaw from his own board?

Read more »

customers inside and outside a Microsoft retail store
International Stock News

Microsoft shares earnings report: What's the verdict?

Investors moved the Microsoft share price significantly.

Read more »

Warren Buffett
International Stock News

Countdown to Berkshire's AGM: What do investors expect to hear from Warren Buffett this year?

All eyes will be on Omaha, Nebraska this weekend.

Read more »

A smiling woman holds a Facebook like sign above her head.
International Stock News

Meta surges on blockbuster earnings report

It's a good day to be a Meta investor.

Read more »

A family sits on their couch, eyes glued to the television.
International Stock News

Can Netflix be a $1 trillion company by 2030?

How much more can it grow its subscription base?

Read more »